Jeremy Archer, MD
Urology · Tupelo, MSNPI 1386179232
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,620 of the $5,711 with a category attached, or 80.9%. 29 manufacturers reported payments, led by Boston Scientific at 33.8% of the total. 2025 is the largest year on record at $2,880, 7.9 times the $365 reported in 2022.
Across 140 payments — averaging $40.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Urogen Pharma, Inc.$407
- Axonics, Inc.$405
- Sumitomo Pharma America, Inc.$361
- Medtronic$354
- Procept Biorobotics Corporation$255
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,09119%
- Food & beverage$4,62081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $1,931 |
| Urogen Pharma, Inc. | 10 | $407 |
| Axonics, Inc. | 18 | $405 |
| Sumitomo Pharma America, Inc. | 17 | $361 |
| Medtronic | 7 | $354 |
| Procept Biorobotics Corporation | 2 | $255 |
| Teleflex LLC | 2 | $249 |
| Merck | 9 | $198 |
| Dendreon Pharmaceuticals LLC | 3 | $188 |
| Astellas Pharma US Inc | 6 | $181 |
| Pfizer | 9 | $159 |
| Ambu Inc. | 1 | $138 |
| Endo USA, Inc. | 3 | $99 |
| Laborie Medical Technologies Corp. | 1 | $96 |
| Bayer | 5 | $89 |
| AbbVie | 5 | $83 |
| Immunitybio, Inc. | 3 | $75 |
| 180 Medical, Inc. | 3 | $74 |
| Johnson & Johnson | 3 | $66 |
| Coloplast | 2 | $59 |
| Olympus America Inc. | 3 | $56 |
| Myriad Genetic Laboratories, Inc. | 3 | $53 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Intuitive Surgical | 2 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Innovation Technologies Inc | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Calyxo, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BPH$1,091
- Lumenis Pulse 120H$376
- AquaBeam Robotic System$255
- INTERSTIM$246
- Barrigel$180
- JELMYTO$158
- PROVENGE$136
- Axonics$120
How this compares
$5,711 in reported general payments places this provider in the 65th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 42 | $108,008 |
| MyrbetriqMirabegron | 34 | $16,331 |
| GemtesaVibegron | 21 | $9,833 |
| Methenamine Hippurate | 103 | $6,509 |
| Tamsulosin Hcl | 179 | $1,130 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $622 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $604 |
| Oxycodone Hcl | 140 | $404 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 148 | $334 |
| Finasteride | 36 | $319 |
| Ondansetron Hcl | 80 | $306 |
| Oxybutynin Chloride | 43 | $249 |
| Ketorolac Tromethamine | 16 | $237 |
| Fluconazole | 18 | $221 |
| Ciprofloxacin Hcl | 28 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $361 | $117,84163 claims |
| Astellas Pharma US IncMyrbetriq | $181 | $16,33134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 urology providers in Mississippi.
Other urology in Tupelo
- Kristopher WhiteheadTupelo$17K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Jonathan KalishTupelo$4K
- William MilamTupelo$2K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Harold BlalockJackson$15K
- Patrick DailyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.